Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.